Blue Cross Blue Shield - Tennessee Prior Authorization Lookup
- Blue Cross Blue Shield - Tennessee coverage criteria
- All Blue Cross Blue Shield - Tennessee policy updates
Latest Blue Cross Blue Shield - Tennessee prior authorization updates25
- Prior AuthClinical/Medical PolicyEff. 2027-01-30Axicabtagene Ciloleucel (Yescarta®)This policy governs coverage and prior authorization for axicabtagene ciloleucel in adult and pediatric patients with specified B-cell lymphomas and related compendial indications. Coverage requires applicable clinical criteria, documentation, and absence of listed exclusions.All blue cross blue shield - tennessee updates
- Prior AuthClinical/Medical PolicyEff. 2027-01-30Bendamustine Products Coverage CriteriaPrior authorization and coverage criteria for bendamustine products used to treat specified hematologic malignancies and related conditions in Tennessee.All blue cross blue shield - tennessee updates
- Prior AuthClinical/Medical PolicyEff. 2027-01-30Collagenase Clostridium Histolyticum (Xiaflex)Coverage and prior authorization requirements for Xiaflex in adult members with Dupuytren's contracture or Peyronie's disease, including clinical criteria, documentation, administration, and quantity limits.All blue cross blue shield - tennessee updates
- Prior AuthClinical/Medical PolicyEff. 2027-01-30Gemcitabine (Inlexzo™) intravesical systemCoverage and prior authorization for Inlexzo in adult members with high-risk, BCG-unresponsive nonmuscle invasive bladder cancer, subject to documented indication, treatment regimen, and continuation criteria.All blue cross blue shield - tennessee updates
- Prior AuthClinical/Medical PolicyEff. 2027-01-30Mitomycin (Zusduri)This policy governs prior authorization coverage of intravesical Zusduri (mitomycin) for adult members with recurrent low-grade intermediate-risk non-muscle invasive bladder cancer and compendial non-muscle invasive bladder cancer use. Coverage requires satisfaction of the stated treatment criteria and absence of exclusions.All blue cross blue shield - tennessee updates
- Prior AuthClinical/Medical PolicyEff. 2027-01-30Multiple Sclerosis Products: Ocrevus, Ocrevus Zunovo, and BriumviThis policy governs coverage and prior authorization for Briumvi, Ocrevus, and Ocrevus Zunovo used to treat specified forms of multiple sclerosis and clinically isolated syndrome when stated approval criteria are met, subject to the member’s benefit plan and exclusions.All blue cross blue shield - tennessee updates
- Prior AuthClinical/Medical PolicyEff. 2027-01-30Nadofaragene firadenovec-vncg (Adstiladrin) Coverage CriteriaThis policy governs prior authorization and medical-necessity coverage for Adstiladrin in adult members with eligible high-risk, BCG-unresponsive non-muscle invasive bladder cancer. Coverage requires applicable clinical criteria and supporting documentation; other indications are not medically necessary.All blue cross blue shield - tennessee updates
- Prior AuthClinical/Medical PolicyEff. 2027-01-30Nipocalimab-aahu (Imaavy) Coverage CriteriaPrior authorization, step therapy, and continued coverage criteria for nipocalimab-aahu (Imaavy) in eligible members with generalized myasthenia gravis or warm autoimmune hemolytic anemia.All blue cross blue shield - tennessee updates
- Prior AuthClinical/Medical PolicyEff. 2027-01-30Tisagenlecleucel (Kymriah®) Coverage CriteriaThis policy governs prior authorization and medical-necessity coverage for tisagenlecleucel (Kymriah) for specified pediatric, young adult, and adult B-cell leukemias and lymphomas. Coverage requires applicable clinical criteria, documentation, and absence of listed exclusions.All blue cross blue shield - tennessee updates
- Prior AuthClinical/Medical PolicyEff. 2027-01-30Vutrisiran (Amvuttra) CoveragePrior authorization and reauthorization for vutrisiran in adults with hereditary transthyretin-mediated amyloidosis polyneuropathy or wild-type/hereditary transthyretin-mediated amyloidosis cardiomyopathy, subject to clinical, diagnostic, prescriber, documentation, and non-combination criteria.All blue cross blue shield - tennessee updates
- Prior AuthClinical/Medical PolicyEff. 2026-12-31Aflibercept ProductsThis policy governs prior authorization and coverage criteria for intravitreal aflibercept products used to treat specified retinal diseases. Coverage applies when the listed indication, prescriber, and clinical response requirements are met; the member’s benefit plan or applicable government program controls if it conflicts with this policy.All blue cross blue shield - tennessee updates
- Prior AuthClinical/Medical PolicyEff. 2026-12-31Atezolizumab and Hyaluronidase-tqjs (Tecentriq Hybreza) Coverage CriteriaThis policy governs prior authorization coverage for Tecentriq Hybreza for FDA-approved and compendial oncology indications. It applies to members whose prescribed therapy meets the listed clinical criteria and has no applicable exclusions; plan terms or government program requirements control if they conflict with the policy.All blue cross blue shield - tennessee updates
- Prior AuthClinical/Medical PolicyEff. 2026-12-31Brentuximab Vedotin (Adcetris®) Coverage CriteriaCoverage and prior authorization for intravenous brentuximab vedotin for specified CD30-expressing lymphomas and related hematologic malignancies when applicable indication, regimen, documentation, and continuation requirements are met.All blue cross blue shield - tennessee updates
- Prior AuthClinical/Medical PolicyEff. 2026-12-31C1 Esterase Inhibitor Subcutaneous (Human) Haegarda®This policy governs prior authorization and coverage of subcutaneous human C1 esterase inhibitor (Haegarda) for prevention of hereditary angioedema attacks in eligible members who meet diagnostic, laboratory, treatment-response, and prescriber requirements, subject to plan terms and exclusions.All blue cross blue shield - tennessee updates
- Prior AuthClinical/Medical PolicyEff. 2026-12-31Durvalumab (Imfinzi®)This policy governs coverage and prior authorization for durvalumab (Imfinzi) for FDA-approved and specified compendial cancer indications. Coverage requires that applicable approval criteria are met and that the member has no exclusion to the prescribed therapy.All blue cross blue shield - tennessee updates
- Prior AuthClinical/Medical PolicyEff. 2026-12-31Efgartigimod Alfa-fcab (Vyvgart); Efgartigimod Alfa-fcab and Hyaluronidase-qvfc (Vyvgart Hytrulo)This policy governs prior authorization and continuation coverage for Vyvgart and Vyvgart Hytrulo in adults with generalized myasthenia gravis, and for Vyvgart Hytrulo in adults with chronic inflammatory demyelinating polyneuropathy. Coverage requires applicable clinical criteria, documentation, and prescribing by or consultation with a neurologist.All blue cross blue shield - tennessee updates
- Prior AuthClinical/Medical PolicyEff. 2026-12-31Inotersen (Tegsedi)Prior authorization coverage for inotersen (Tegsedi) to treat polyneuropathy associated with hereditary transthyretin-mediated amyloidosis in adults, subject to diagnostic, clinical, specialist, and authorization criteria.All blue cross blue shield - tennessee updates
- Prior AuthClinical/Medical PolicyEff. 2026-12-31Ipilimumab (Yervoy) Coverage CriteriaThis policy governs coverage and prior authorization for ipilimumab (Yervoy), alone or in specified combinations, for FDA-approved and compendial oncology indications. Covered use requires satisfaction of the applicable approval criteria and absence of exclusions; all other indications are considered experimental/investigational and not medically necessary.All blue cross blue shield - tennessee updates
- Prior AuthClinical/Medical PolicyEff. 2026-12-31Pemetrexed CoverageCoverage and prior authorization for pemetrexed products used for specified FDA-approved and compendial oncology indications when the applicable disease, regimen, and approval criteria are met.All blue cross blue shield - tennessee updates
- Prior AuthClinical/Medical PolicyEff. 2026-12-31Teplizumab-mzwv (Tzield) Coverage PolicyThis policy governs prior authorization and medical necessity criteria for Tzield to delay the onset of Stage 3 type 1 diabetes or delay decline in endogenous insulin production in recently diagnosed Stage 3 type 1 diabetes, subject to specified clinical, age, prescriber, documentation, and treatment-course requirements.All blue cross blue shield - tennessee updates
- Prior AuthClinical/Medical PolicyEff. 2026-12-01Agalsidase Beta (Fabrazyme®) Coverage for Fabry DiseaseThis policy governs prior authorization and coverage of intravenous Fabrazyme for adult and pediatric members aged 2 years and older with confirmed Fabry disease. Coverage requires clinical, diagnostic, prescriber-specialty, and non-combination-use criteria; other indications are not medically necessary.All blue cross blue shield - tennessee updates
- Prior AuthClinical/Medical PolicyEff. 2026-12-01Leuprolide Acetate Depot Suspension (Lupron Depot-Ped®)This policy establishes prior authorization and medical necessity criteria for leuprolide acetate depot suspension for pediatric central precocious puberty and gender-affirming care, including clinical, documentation, and prescriber requirements.All blue cross blue shield - tennessee updates
- Prior AuthClinical/Medical PolicyEff. 2026-12-01Leuprolide Mesylate (Camcevi ETM™; Camcevi Kit)This policy governs prior authorization and coverage criteria for Camcevi (leuprolide mesylate) for adult advanced prostate cancer and specified salivary gland tumors for BlueCross BlueShield of Tennessee members.All blue cross blue shield - tennessee updates
- Prior AuthClinical/Medical PolicyEff. 2026-12-01Mepolizumab (Nucala) Coverage CriteriaCoverage and prior authorization requirements for mepolizumab (Nucala) for specified FDA-approved indications and compendial uses, including chronic rhinosinusitis with nasal polyps, severe eosinophilic asthma, eosinophilic COPD, hypereosinophilic syndrome, and eosinophilic granulomatosis with polyangiitis.All blue cross blue shield - tennessee updates
- Prior AuthClinical/Medical PolicyEff. 2026-12-01Mirikizumab-mrkz (Omvoh) Coverage CriteriaThis policy governs prior authorization and coverage of mirikizumab-mrkz (Omvoh) for adults with moderately to severely active ulcerative colitis or Crohn's disease, including prescriber, documentation, clinical response, safety, and continuation requirements.All blue cross blue shield - tennessee updates
Tool Description
Search Blue Cross Blue Shield - Tennesseeprior authorization policies by drug name, procedure, or policy title. Results include any policy that mentions prior authorization requirements (drug coverage criteria, imaging guidelines, site-of-service rules) not just documents titled “prior authorization.” Every result links to a full policy page with clinical criteria, covered billing codes, documentation requirements, and effective dates.
Filter by payer, specialty, policy type, or effective year; or search directly for a drug (“Wegovy,” “Ozempic”), a procedure (“MRI,” “knee arthroplasty”), or a policy number.
Coverage spans 110+ payers. Jump straight to the busiest prior-auth publishers: UnitedHealthcare, Cigna, Aetna, Anthem, and Centene. You can also browse the full policy updates feed.
Pair a prior-auth search with the billing code lookup to confirm the CPT or J-code on the claim, the payer lookup for plan footprint, and payer profiles for contacts and coverage context.
FAQ
Prior Authorization by Payer
Go deeper
Explore OpenPayer Data
Prior auth requirements change all the time. Keep up with every payer policy update in the live policy feed, or browse payers with prior authorization policies.
Toolbox
More OpenPayer Tools
- Billing Code LookupSearch CPT, HCPCS, J-codes, DRG, and dental codes by number or procedure name.
- Billing Code Reimbursement RatesBuild a reimbursement rate report across any mix of billing codes and states, comparing commercial payers against Medicare.
- Payer Comparison DashboardPick 2-5 payers to compare market share, premium, and membership by region, all at once.
- Facility Comparison DashboardPick 2-6 hospital facility types (or add a specific hospital) to compare facility count, revenue, net income, and Medicare/Medicaid payer mix by region, all at once.
- Healthcare Provider & Facility LookupFind hospitals and healthcare facilities by name, taxonomy, facility type, ownership, or state.
- Health Insurance Payer LookupSearch national health insurance payers and health plans by name and state presence.
- Provider Taxonomy Code LookupSearch NUCC taxonomy codes by code, specialty, grouping, or classification.
- CPT Modifier LookupSearch CPT modifiers by code or name — descriptions, when to use them, and payer policy context.
- Timely Filing LookupFind payer timely filing policies: claim deadlines, corrected claim windows, and appeal timeframes.
- Coverage Criteria LookupSearch payer coverage criteria and medical necessity requirements by drug, procedure, or payer.
- Payer Contact DirectoryClaims, prior authorization, provider services, and appeals contacts for health insurance payers.
Trek Health powers OpenPayer with a leading commercial payer intelligence platform, seamlessly converting fragmented payer data into actionable insights for provider organizations.